Performance and Practicality of 16S Nanopore Sequencing for Routine

Bacterial Identification in Clinical Samples

Authors: A.U. Geers[1], C. Bütikofer[1], M. A. Terrazos Miani[1], S. Droz[1], A. Zihler Berner[1], I. Lendenmann[1],

C. Hirzel[2,3], P.M. Keller[4,5], F. Suter-Riniker[1,2], S. Neuenschwander[1], C. Casanova[1,2], A. Ramette[1,2*]

[1]Institute for Infectious Diseases, University of Bern, Bern, Switzerland

[2]Multidisciplinary Center for Infectious Diseases, University of Bern, Bern, Switzerland

[3]Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

[4]Division of Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland

[5]Center for Infectious Disease Diagnostics, University Hospital Basel, Basel, Switzerland

*Correspondence: Alban Ramette. Institute for Infectious Diseases, University of Bern,

Friedbühlstrasse 25, Bern 3001, Switzerland. Tel +41 31 684 19 08, Email alban.ramette@unibe.ch

Keywords: low-biomass samples – clinical Microbiology – NGS – Nanopore – 16S rRNA gene –

bacterial infections

Abstract

The accurate identification of bacterial pathogens is a critical step in clinical diagnostics, directly impacting effective treatment and patient outcomes. This study addresses the need for standardized, clinically validated protocols for routine infectious disease diagnostics, particularly within the context of low-diversity clinical samples. We validated the performance of a 16S nanopore-based (Oxford Nanopore Technologies [ONT]) sequencing pipeline against an established Illumina Next-Generation Sequencing (NGS) workflow. We first investigated the detection limits and capabilities of ONT and Illumina using dilution series experiments of pure and mixed bacterial cultures. Subsequently, the validated pipeline was prospectively applied to 101 clinical samples, and the results were evaluated in parallel with Illumina data and by clinical review to determine infection plausibility. Species detection patterns and relative abundances demonstrated high consistency between ONT and Illumina across the clinical cohort, achieving an overall read overlap of 93.5% ± 7.6% and a high level of agreement upon clinical review. While Illumina sequencing exhibited slightly greater sensitivity at very low microbial loads in dilution experiments, ONT generated sequences with higher average accuracy (99.8% ± 0.39 vs. 99.8% ± 0.42%). Crucially, the Nanopore workflow demonstrated superior efficiency, requiring approximately 50 hours less total time and proving to be significantly more cost-effective than the Illumina workflow. These findings indicate that 16S nanopore sequencing provides comparable performance to Illumina sequencing for clinical bacterial identification in low-diversity samples. We conclude that 16S nanopore sequencing is a feasible, time-effective, and cost-effective method suitable for direct implementation in routine clinical diagnostic workflows.

1 Introduction

The identification of bacterial pathogens is a critical step in clinical diagnostics, guiding effective treatment and improving patient outcomes. Traditionally, this process has relied on culture-based methods, which can be time-consuming and may fail, due to factors such as prior antibiotic exposure (1) or fastidious growing organisms (2). In recent years, culture-independent approaches, particularly sequencing of the 16S rRNA gene, have become more widely adopted in clinical settings due to their ability to provide rapid taxonomic identification directly from patient samples (3–6). This approach is especially advantageous for complex and urgent cases where timely results are crucial or for samples that yield inconclusive or negative results with conventional culture. Particularly challenging to diagnose are samples with low-bacterial diversity, such as specimens from sterile body sites, since reagent contamination can lead to significant over estimation of potential pathogens (7). Thus, using DNA-free reagents is crucial to limit the detection of false positives. Several sequencing technologies are available for 16S rRNA gene amplicon sequencing. While traditional Sanger sequencing remains widely used due to its low cost and speed, its inability to resolve complex mixtures of bacteria limit its effectiveness for polymicrobial infections (3, 4). Next-generation sequencing (NGS) platforms, such as those from Illumina, offer high precision and throughput. However, the short read lengths produced by Illumina can sometimes limit the ability to achieve species-level taxonomic resolution, particularly for closely related bacteria (2). Additionally, their high hardware costs and the requirement for large sample batches to be cost-effective are significant barriers to implementation in a rapid, on-demand clinical diagnostic workflow.

Third-generation sequencing technologies, most notably Oxford Nanopore Technologies (ONT), present a promising alternative. Nanopore sequencing offers advantages that are particularly well-suited for clinical microbiology, including rapid sample-to-result turnaround times, low initial hardware expenditure, and the ability to process single or small batches of samples efficiently (8, 9). Its portability allows for decentralized testing, further reducing time to diagnosis (10). While ONT sequencing has been associated with a higher rate of sequencing errors compared to Illumina, its capacity to generate long reads spanning the full-length 16S rRNA gene can offer superior taxonomic resolution (8). Despite its potential, the clinical adoption of 16S nanopore sequencing is hindered by the lack of standardized and clinically validated protocols. A comprehensive and direct comparison to established NGS methods like Illumina, especially using a large cohort of clinical samples, has also been lacking. Our study addresses these critical gaps by presenting a clinically tested and used pipeline for 16S nanopore sequencing in routine infectious disease diagnostics. We implemented a cost- and time-effective pipeline utilizing an in vitro diagnostic (IVD) certified amplification protocol that targets the

76 V3-V4 region of the 16S rRNA gene using DNA-free reagents. The pipeline's accuracy was validated on

77 over 100 patient samples, with results confirmed by comparative Illumina sequencing and subjected

78 to rigorous clinical evaluation against the corresponding patient medical history.

2   Methods

Clinical samples and pure bacterial cultures

Clinical samples originated from the Insel Gruppe, the largest Swiss hospital group, and were analyzed

at the Institute for Infectious Diseases (IFIK) in Bern. The diagnostic division of IFIK (clinical

microbiology) is accredited under EN ISO/IEC 17025 to conduct routine bacterial diagnostics on clinical

samples. Clinical samples were routinely analyzed with eubacterial 16S PCR and ONT sequencing as

described below. The samples were retroactively also sequenced with Illumina. The Ethics Committee

of the Canton of Bern (BASEC-Nr 2024-00640) approved this study. For dilution series experiments, *S.*

aureus (ATCC 25923) and *E. coli* (ATCC 25922) were grown in 5 ml Luria Broth (LB) liquid culture for 2

h, and subsequently diluted to 10^{-5}, 10^{-6}, and 10^{-7} in LB. Additionally, undiluted *E. coli* and *S. aureus*

liquid cultures were mixed in a ratio of 1:2. The resulting mixture was diluted to 10^{-5}, 10^{-6}, and 10^{-7} in

LB (**Figure 1**). 1 ml of each of the diluted liquid cultures was used for further DNA extraction and

sequencing (see below), and the liquid cultures were plated on MAC (MacConkey II Agar, Becton

Dickinson) and CNA (Columbia CNA Agar, Becton Dickinson) plates to determine bacterial counts

(colony forming units; CFU).

DNA extraction and PCR amplification

The commercial Micro-Dx kit (Molzym, Bremen, Germany) was used for automated microbial DNA

enrichment, host depletion, microbial DNA extraction and real-time 16S PCR (**Figure 1**). The

manufacturer's protocol was followed. In the case of positive PCR result, the PCR product was purified

and used for sequencing. PCR mixtures (28 µl) were assembled with 10 µl master mix containing 7.5 µl

water, 2.5 µl DNA staining solution and 0.8 µl MolTaq 16S (DNA polymerase; Molzym). Real-time 16S

PCR was performed in a LightCycler z480 (Roche) with the following parameters: 95°C for 1 min; 40

cycles of 95°C for 5 s, 55°C for 10 s, 72°C for 25 s; and 40°C for 10 s. PCR products were purified with

AMPure XP beads (Beckman coulter, Brea, California) following the manufacturer's protocol with

minor modifications: An additional 3s centrifugation step was added after the washing step, and the

purified DNA was eluted in 80 µl of Tris-HCl (0.01 M, pH 8.0). Amplicon fragment sizes were assessed

using the TapeStation D1000 assay (Agilent, Santa Clara, CA, USA), and DNA concentrations were

determined with the Qubit double-stranded DNA (dsDNA) broad-range (BR) assay (Thermo Fisher

Scientific, Reinach, Switzerland).

To control for contaminations, we used a total of 14 negative controls (i.e. sterile double-distilled
water), including five controls from the DNA extraction step, five controls from the eubacterial PCR
step, four from library prep Illumina steps. We were only able to successfully identify species in three
negative controls (one extraction negative, two eubacterial PCR negative controls). The species
identified in the extraction or PCR negative controls could not be identified in samples from the same
extraction and PCR batch, with the exception of one species of *Actinomycetales* bacterium
(**Supplementary Figure 1**).

Library preparation and sequencing

Library preparation for ONT sequencing was performed with the kit SQK NBD114.24 (ONT, Oxford, UK)
using the supplementary reagents NEBNext Ultra II End repair/dA tailing Module (New England Biolabs
[NEB], ON, CA), NEB Blunt/TA Ligase Master Mix (M0367; NEB) and NEBNext Quick Ligation Module
(NEB). The manufacturer's protocol (REF NBA_9168_v114_revO_15Sep2022) was modified as follows:
Diluted DNA Control Sample (DCS) was not used for End Prep (EP) step, DCS volume was substituted
with nuclease free water (NFW). No clean-up and no normalization were performed after EP.
Therefore, 3 µl of End Prep Product with 4.5 µl NFW was used for barcoding step instead of 7.5
normalized EP product. Ethanol (80%) was used for the post-barcoding washes instead of Short
Fragment Buffer (SFB). SFB was used for clean-up step after adapter ligation. A typical library consisted
of the pooling of PCR amplicons from 1 to 20 clinical samples, two positive controls (*Streptococcus*
agalactiae amplicons), one extraction negative and one PCR negative samples. ONT libraries were
sequenced on GridION X5 sequencers with the standard flowcells (FLO-MIN114) with real-time
basecalling under high accuracy mode (HAC), for up to 1 h or until the positive controls reached at least
10,000 reads.

Library preparation for Illumina sequencing was performed with the KAPA Unique Dual-Indexed
Adapter Kit KR1736 – v2.19 and the KAPA HyperPrep Kit KR0961 – v7.19. The protocol was followed
according to the manufacturer's instructions, with the exception of using CleanNGS DNA Beads instead
of the KAPA cleanup beads, and two additional clean-up steps with beads after amplification. Each
library consisted of 68 to 76 pooled clinical samples and negative controls. The library was sequenced
on an Illumina MiSeq sequencer with v2 reagents in 2x250bp paired-end mode. Both ONT and Illumina
sequencing were performed at the Institute for Infectious Diseases, University Bern.

Bioinformatic analyses

ONT reads were demultiplexed and analyzed with the LORCAN pipeline (11). In brief, the adapters are
trimmed, filtered by length (± 100 bp around modal sequence length; i.e. 320-520 bp), and subsampled
to a maximum of 9,000 reads (**Figure 1**). Then the reads are grouped into species by mapping to a

custom nonredundant reference database. Detailed instructions for database creation can be found online: https://github.com/aramette/ LORCAN/. In brief the reference database, LeBiBi SSU-rDNA-mk45 (12) was trimmed to the region of interest, dereplicated (mothur; version v.1.48.0 (13)), and used to make a custom database. Only species groups with at least 100 reads are further processed. For each species group, the reads are remapped to the reference sequence with the highest number of mapped reads, and the consensus sequence is generated using a 50% majority rule consensus. In a last step, the consensus sequences are mapped again to the custom database using BLAST (v2.12.0) to identify the closest taxonomic neighbors (**Figure 1**).

The basecalled and demultiplexed Illumina reads were trimmed, quality filtered (fastp v 0.23.2, enabled base correction in overlapped regions, min Phred quality of 20), end trimmed (24 bp) and filtered for minimum length of 240 bp (DADA2, v1.34 (14)). Subsequently the reads were denoised, merged and amplicon sequencing variants (ASVs) generated using the established DADA2 (v1.3.4) pipeline (14). The resulting ASVs were again filtered for a minimum length of 390 bp and maximum of 450 bp and their taxonomy was determined by mapping to the reference database using BLAST (v2.12.0). In a last step read counts were combined at species level and all species with less than 100 reads were filtered out (**Figure 1**). Read counts were processed with R version (4.4.1), using the packages tidyverse (v2.2.0), data.table (v.17.2), RColorBrewer (v1.1-3), ggvenn (v0.1.10), ggpubr (v0.6.0), ggtext (v0.1.2), svglite (v2.21), to generate the figures and perform statistical analyses.

Data availability

Raw sequencing data is available under the BioProject accession number: PRJEB102560.

Supplementary tables can be accessed under: 10.5281/zenodo.17811713.

3   Results

Dilution series. We assessed the detection capabilities of ONT and Illumina sequencing on pure cultures of *E. coli* and *S. aureus*, and on a mixture of the two at a ratio of 2:1. Samples were prepared in a dilution series of 10^{-5}, 10^{-6}, and 10^{-7} in triplicates, corresponding to average CFU counts of 3,040, 310, 30 for *E. coli*, and 2,590, 80, 0 for *S. aureus*, respectively. In the mixture there were an average of 34,270, 8,330, 2,110 *E. coli* CFU and 14,600, 6,150, 910 *S. aureus* CFUs in the respective dilutions. All samples were sequenced with both technologies. Additionally, we analysed a subsample of 9,000 Illumina reads per sample, which represents the maximum number of reads considered in the ONT analysis, to assess the impact of sequencing depth on the results. On average we obtained 1040 raw reads with ONT sequencing and 186,040 raw reads with Illumina sequencing for our dilution series

(**Supplementary table 1**). During the bioinformatic analysis, sequences identified as *Escherichia* sp.

and *Shigella* sp. were grouped together due to the high genetic similarity of their 16S rRNA gene and

the resulting inability of V3V4 16S sequencing to distinguish them (15). Similarly, we made the decision

to regroup sequences for *Corynebacterium* spp. together. At the highest concentrations, both

sequencing methods, with either the full or subsampled read sets, successfully detected the correct

species, confirming their ability to identify species present at high concentrations (**Figure 2**). However,

at lower concentrations (<10^{-6} CFU/ml), neither method could detect *E. coli*, suggesting that the true

concentration of this species fell below the limit of detection for both sequencing platforms under

these experimental conditions. For *S. aureus*, detection failed to be reliable at concentrations below

80 CFU/ml; only Illumina sequencing (including the subsampled data) was able to identify the species

at the 10^{-6} dilution in 2 out of 3 replicates, indicating that this method possessed a slightly greater

sensitivity at low microbial loads. In the polymicrobial sample, both methods detected both species

even at the lowest concentration. The observed ratio between the two species was in the same order

of magnitude as for the CFU-based counts. For the dilutions 10^{-5}, 10^{-6}, and 10^{-7} using ONT sequencing,

we observed ratios between *E. coli* and *S. aureus* of 8, 3 and 7, respectively. With Illumina sequencing

these ratios were 4, 2 and 5, respectively (**Figure 2**). Subsampled Illumina reads had no effect on these

ratios. Ratios determined by CFU counts were 2.3, 1.3 and 2.3, respectively. This indicates that

although both methods can accurately identify species within a mixed community, minor differences

in the observed abundances may occur. A notable finding was the more frequent detection of false

positives using Illumina sequencing with the DADA2 pipeline. These false positives included *Paracoccus*

hibiscisoli, *Rhizobium daejeonense*, *Corynebacterium* sp., *Streptococcus parasanguinis*, and

Cutibacterium acnes, among others. These false positives occurred in both the full or subsampled

datasets, indicating that the issue was not related to sequencing depth. We further investigated the

ONT raw reads for the presence of these contaminants, and found them to be present as well, albeit

below the threshold required for generating consensus sequences (**Supplementary Table 2**).

Clinical samples. We analyzed 101 clinical samples from routine diagnostics collected over a 1.5-year

period. These samples represented a diverse range of clinical materials, encompassing 43 distinct

sample types, and were predominantly derived from joint and spine biopsies (**Supplementary Table**

3). All samples underwent sequencing using both ONT and Illumina on the same DNA extracts. Across

both sequencing methods, a total of 167 species were detected with at least 100 assigned reads, and

115 of these species were shared between the two methods (**Figure 3A, Supplementary Table 4**), while

23 species were uniquely detected by ONT and 29 species were exclusively found by Illumina.

Subsampling the Illumina reads reduced the number of detected species, resulting in only 109 shared

species and 5 species unique to Illumina. The prevalence of species across samples was comparable

between methods, with ONT detecting species on average in 2.23 ± 2.97 samples, and Illumina on

average in 2.08 ± 3.11 samples (subsampled Illumina data in 2.18 ± 3.10 samples) (**Figure 3B**).

Cutibacterium acnes was the most common species (in 20 and 30% of the samples, based on ONT and

Illumina sequencing), with average relative abundances of 51% ± 40% with ONT, and 39% ± 41% with

Illumina sequencing (across samples it was present in). Other common species included those from

the *Staphylococcus* and *Streptococcus* genera. We found that the overall species detection pattern was

consistent between the two methods when considering the relative abundances of species within each

sample (**Figure 3B**). Species uniquely detected by either Illumina or ONT generally had lower average

relative abundances (3% on average). Aggregating the abundances of all species across all samples

further showed that the detection patterns for Illumina and ONT were highly similar (**Figure 3C**), and

subsampling the Illumina reads did not significantly alter these trends. Consistent with the prevalence

data, *C. acnes* and several *Staphylococcus* and *Streptococcus* species were highly represented in the

total dataset (**Figure 3C**). As an estimate of bacterial diversity per sample, the average number of

species per sample was 3.0 ± 2.7 for ONT, and 3.0 ± 3.4 for Illumina (2.5 ± 2.3 for the subsampled

Illumina data). Subsampling the Illumina reads significantly reduced the number of species per sample

(paired *t* test, p-value = 0.0007), possibly reducing the number of detected contaminants. To precisely

evaluate the differences between the two methods, we calculated the overlap of species for each

sample. On average, 97.1% ± 5.9%, of species detected by ONT (weighted by their relative abundance)

were also found by Illumina, while 98.7% ± 2.8% of Illumina species (weighted by their relative

abundance) were also detected by ONT. The overall read overlap with the same species between

methods was 93.5% ± 7.6%. Lastly, a comparison of consensus sequence accuracy using BLAST identity

showed that sequences generated by ONT had an average sequence identity to the reference of 99.88

% ± 0.39 (weighted by reads), while Illumina sequences had an average identity of 99.83 % ± 0.42 % to

the reference. This difference was found to be statistically significant (paired *t* test p-value = 0.0001).

Clinician review. An experienced infectiologist reviewed all sequencing results obtained for the clinical

samples in order to evaluate the clinical plausibility of the NGS findings. The review found a high level

of agreement between the two sequencing methods: For 77 (76%) samples, a likely pathogen was

observed, whereas for the remaining 24 samples, the sequencing data suggested a likely

contamination. Importantly, there were no cases where one sequencing method identified a pathogen

and the other identified a contamination in the same sample. We also found that the number of

species detected per sample was significantly higher in samples identified as contaminations compared

to those with a likely pathogen, for both Illumina (p=0.02) and ONT (p=0.03) sequencing (**Figure 3D**).

Furthermore, we assessed the potential impact of patient antibiotic treatment prior to sampling and sequencing, which was documented in 94% of the samples (69 samples with treatment, 26 samples without). There was no significant correlation between antibiotic pretreatment and the number of species detected for either sequencing method. Interestingly, in samples with antibiotic pretreatment significantly more pathogens than contaminations were detected (Fisher exact test, p-value = 0.02) (**Supplementary Tables 3 and 4**).

Cost and turnaround time estimation. We estimated that the consumables for a batch size of 24 samples processed on a single flow cell resulted in approximate per-sample costs of 35 CHF for ONT and 155 CHF for Illumina. The effective price difference is likely to be even greater in routine diagnostic settings, as batch sizes are often smaller than 24 samples. This is primarily because ONT flow cells can be reused if only a small number of samples is sequenced, while Illumina sequencing cartridges are single-use, regardless of the number of sequenced samples. To estimate the turnaround time of the two sequencing approaches, we considered the time required for library preparation, sequencing, and bioinformatic analysis (including data transfer, quality control, and report generation) for a 24-sample batch. The ONT workflow required approximately 5, 2, and 0.5 h for each of the steps, respectively. In contrast, the Illumina workflow required 7, 43, and 0.5 h, respectively. These time estimates for the bioinformatic analysis assume that pre-established and automated pipelines are in place. These findings underscore the ONT-based workflow's advantage in speed, demonstrating a much faster turnaround than the Illumina-based process.

4   Discussion

The study successfully demonstrates that ONT sequencing provides a time- and cost-efficient alternative to established methods of 16S rRNA sequencing in routine clinical diagnostics, especially for low-diversity samples. Using a controlled dilution series and a large panel of 101 routine clinical samples, we showed that ONT 16S rRNA gene sequencing achieves sensitivity and specificity comparable to the gold standard Illumina sequencing. In 76% of clinical samples, it successfully identified a likely pathogen, as confirmed by clinical review of the cases. Furthermore, for batch sizes of around 24 samples, ONT is much more time and cost efficient than Illumina-based workflow.

The limit of detection achieved using the ONT platform in our controlled experiments was in the range of 100 to 1,000 CFUs/ml (**Figure 2**). In a recent study standardizing 16S rRNA gene sequencing for culture-negative infections (16), the authors evaluated ONT sensitivity using DNA genome copies per µl, noting that species detection varied, and observed better sensitivity with the MinION flow cell than

with Flongle, potentially due to differences in sequencing depth. Another investigation that focused

on direct bacterial identification in sterile body fluids estimated a slightly lower detection limit of 90

CFUs/ml (17). This difference is likely attributable to their substantially higher sequencing depth,

reporting approximately ten times more reads per sample than generated in our study. In comparison,

Illumina sequencing demonstrated a slightly lower detection limit in our controlled dilution series

(**Figure 2**), irrespective of whether the full or a subsampled dataset was analyzed. This aligns with

findings from other 16S studies, where Illumina sequencing was observed to capture greater species

richness in respiratory microbial communities (18).

A limitation of our current method is the use of the V3-V4 hypervariable region of the 16S rRNA gene,

instead of the full-length 16S gene. The V3-V4 region is the established universal target in the IVD-R kit

we used, which offers a broad-range detection of >345 bacterial species of clinical relevance (19).

Shorter amplicons are generally assumed to lend themselves to better amplification efficiency in PCR.

For instance, one study found that shorter 16S amplicon had higher sensitivity in their metagenomic

analysis of culture-negative samples (20). However, utilizing the V3-V4 region inherently limits the

taxonomic resolution achievable, as full-length 16S sequencing often provides greater species-level

differentiation, enabling for example the differentiation of *E. coli* from *Shigella* (17), or between

Staphylococcus species (21).

An interesting finding from the controlled dilution experiments was the detection of more

contaminating reads with Illumina than with ONT sequencing, when a minimum threshold of 100 reads

per species for identification was set **(Figure 2)**. However, when examining routine clinical samples,

both sequencing methods appeared equally likely to detect non-pathogenic contaminants **(Figure 3D)**.

Interpreting such low-abundance reads is critical for clinical reporting. One study on mock

communities found that ONT displayed remarkably high accuracy compared to Illumina sequencing

(22), though the use of full-length 16S for ONT and shorter amplicons for Illumina in that study

represents a confounding factor. To address the "tail" of low-abundant species (often contaminants)

observed in sequencing data, prior studies have implemented relative abundance filters, such as

filtering species below 0.1% (21) or 0.06% (17). While filtering by relative abundance worked well for

monomicrobial samples, it was shown to fail for polymicrobial samples (17), underscoring the

complexity of robustly differentiating true pathogens from contaminants in complex clinical scenarios.

We found *Cutibacterium acnes* to be one of the most common species in the investigated clinical

samples **(Figure 3B)**. Because *C. acnes* is a skin commensal and can also be an opportunistic pathogen,

differentiating a true infection from a contamination can be challenging (23). In eleven (=11%) of our

clinical samples *C. acnes* was the likely pathogen as evaluated by the clinical review, while in the

remaining 10-20 samples, the species was detected in, a potential implication as a pathogen could not be unambiguously determined (**Supplementary Tables 3-4**). In those latter cases, *C. acnes* presence might thus represent a contamination occurring during the sampling or laboratory processes. The elevated prevalence of *C. acnes* may also be attributable to the significant proportion of joint biopsies within our clinical samples. *C. acnes* has gained notoriety for its role in implant-associated infections and has also been recognized as a significant pathogen in cerebrovascular infections, breast implant fibrosis, and cardiovascular device infections (23).

Overall, we observed an average species overlap of 93.5% (weighted by abundance) between the two platforms. This direct comparison, conducted on a large set of routine clinical specimens prospectively collected over 18 months, confirms that ONT sequencing is equally effective and accurate as the current gold NGS standard, Illumina sequencing, for clinical pathogen diagnostics. Furthermore, the ONT platform in combination with the LORCAN bioinformatic pipeline demonstrated a slightly higher consensus sequences accuracy (99.88% ± 0.39% sequence identity to reference) compared to sequences generated by Illumina and DADA2 (14) (99.83% ± 0.42%). While there are multiple studies exploring the feasibility of ONT 16S rRNA gene sequencing in diagnostics, primarily comparing results to culture (17, 24–27), MALDI-TOF (28, 29), or Sanger sequencing (10, 16, 20, 29), there is a notable absence of studies directly comparing ONT versus Illumina sequencing using a large cohort of clinical samples. A small scale study found that the microbial composition determined with Illumina V3-V4 sequencing closely matched to the one determined with ONT full-length sequencing in tracheal aspirates samples (21), as well as in a mock community. Similarly, an older study in 2019 showed both technologies could accurately identify bacterial genera in a well-characterized reference sample (22).

Overall, ONT sequencing holds a very positive outlook in clinical diagnostics of low-diversity samples, primarily due to its proven advantages in shorter turnaround time and cost efficiency, especially with small batch sizes. The successful demonstration that ONT sequencing achieves sensitivity and specificity comparable to the gold standard Illumina sequencing, confirms its viability as a mainstream clinical tool. Future efforts should prioritize maximizing the platform's utility by addressing current limitations. Specifically, using longer sequences or complementary genetic targets could be crucial to enhance taxonomic resolution (30), especially in combination with full-length curated databases of 16S rRNA genes (31–33). Finally, continued development is necessary for robust bioinformatic strategies to accurately interpret low-abundance reads, which represent contaminants, especially in complex clinical scenarios where filtering methods successful for monomicrobial samples may fail for polymicrobial samples.

5 References

1. Sigakis MJG, Jewell E, Maile MD, Cinti SK, Bateman BT, Engoren M. 2019. Culture-Negative and Culture-Positive Sepsis: A Comparison of Characteristics and Outcomes. Anesthesia & Analgesia 129:1300.

2. Church DL, Cerutti L, Gürtler A, Griener T, Zelazny A, Emler S. 2020. Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory. Clinical Microbiology Reviews 33:10.1128/cmr.00053-19.

3. Youssef N, Boutros CF, Dakroub F, Akl F, Reslan L, Finianos M, Moumneh MBM, Dargham TB, Zein ZE, Haddara A, Korman R, Khafaja S, Matar G, Araj GF, Dbaibo GS. 2025. The clinical impact of 16S ribosomal RNA PCR and sequencing in the identification of bacterial infections: a 7-year report from a Lebanese tertiary care center. Front Cell Infect Microbiol 15.

4. Flurin L, Wolf MJ, Mutchler MM, Daniels ML, Wengenack NL, Patel R. 2022. Targeted Metagenomic Sequencing-based Approach Applied to 2146 Tissue and Body Fluid Samples in Routine Clinical Practice. Clinical Infectious Diseases 75:1800–1808.

5. Botan A, Campisciano G, Zerbato V, Di Bella S, Simonetti O, Busetti M, Toc DA, Luzzati R, Comar M. 2024. Performance of 16S rRNA Gene Next-Generation Sequencing and the Culture Method in the Detection of Bacteria in Clinical Specimens. 13. Diagnostics 14:1318.

6. Poulsen SH, Søgaard KK, Fuursted K, Nielsen HL. 2023. Evaluating the diagnostic accuracy and clinical utility of 16S and 18S rRNA gene targeted next-generation sequencing based on five years of clinical experience. Infectious Diseases.

7. Egli K, Risch M, Risch L, Bodmer T. 2022. Comparison of an automated DNA extraction and 16S rDNA real time PCR/sequencing diagnostic method using optimized reagents with culture during a 15-month study using specimens from sterile body sites. BMC Microbiology 22:119.

8. Ivens MJR, Kamminga S, Benchamach K, Akile C, Wessels E, Claas ECJ, Boers SA. 2025. Rapid and reliable species-level identification from clinical samples using 16 S rRNA gene nanopore sequencing analysis. Sci Rep 15:28606.

9. Brunet S, Grankvist A, Jaen-Luchoro D, Bergdahl M, Tison J-L, Wester A, Elfving K, Brandenburg J, Gullsby K, Lindsten C, Arvidsson L-O, Larsson H, Eilers H, Strand AS, Lannefors M, Keskitalo J, Rylander F, Welander J, Jungestrom MB, Geörg M, Kaden R, Karlsson I, Linde A-M, Mernelius S, Berglind L, Feuk L, Kerje S, Karlsson L, Sjödin A, Guerra-Blomqvist L, Wallin F, Fagerström A, Vondracek M, Mölling P, Hallbäck ET. 2025. Nationwide multicentre study of Nanopore long-read sequencing for 16S rRNA-species identification. Eur J Clin Microbiol Infect Dis 44:1907–1916.

10. Carlisle D, Cunningham-Oakes E, Booth J, Frankland A, McDowell M, Pilgrim J, Rzeszutek A, Evans C, Larkin S, Li A, Loftus C, Samuel M, Scott N, Swithenbank L, Owen V, Darby AC, Smielewska A.

2024. Implementing portable, real-time 16S rRNA sequencing in the healthcare sector enhances
antimicrobial stewardship. medRxiv https://doi.org/10.1101/2024.09.23.24314079.

11. Neuenschwander SM, Terrazos Miani MA, Amlang H, Perroulaz C, Bittel P, Casanova C, Droz S,
Flandrois J-P, Leib SL, Suter-Riniker F, Ramette A. 2020. A Sample-to-Report Solution for
Taxonomic Identification of Cultured Bacteria in the Clinical Setting Based on Nanopore
Sequencing. Journal of Clinical Microbiology 58:10.1128/jcm.00060-20.

12. Flandrois J-P, Perrière G, Gouy M. 2015. leBIBIQBPP: a set of databases and a webtool for
automatic phylogenetic analysis of prokaryotic sequences. BMC Bioinformatics 16:251.

13. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB,
Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF. 2009. Introducing
mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing
and Comparing Microbial Communities. Applied and Environmental Microbiology 75:7537–7541.

14. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2: High-
resolution sample inference from Illumina amplicon data. Nat Methods 13:581–583.

15. Devanga Ragupathi NK, Muthuirulandi Sethuvel DP, Inbanathan FY, Veeraraghavan B. 2018.
Accurate differentiation of *Escherichia coli* and *Shigella* serogroups: challenges and strategies.
New Microbes and New Infections 21:58–62.

16. Butler I, Turner O, Mohammed K, Akhtar M, Evans D, Lambourne J, Harris K, O'Sullivan DM,
Sergaki C. 2025. Standardization of 16S rRNA gene sequencing using nanopore long read
sequencing technology for clinical diagnosis of culture negative infections. Front Cell Infect
Microbiol 15:1517208.

17. Lao H-Y, Wong LL-Y, Hui Y, Ng TT-L, Chan CT-M, Lo HW-H, Yau MC-Y, Leung EC-M, Wong RC-W,
Ho AY-M, Yip K-T, Lam JY-W, Chow VC-Y, Luk KS, Que T-L, Chow FWN, Siu GK-H. 2024. The clinical
utility of Nanopore 16S rRNA gene sequencing for direct bacterial identification in normally
sterile body fluids. Front Microbiol 14.

18. Macip G, Soler-Comas A, Palomeque A, Motos A, Llonch B, Canseco-Ribas J, Bueno-Freire L,
Calabretta D, Kiarostami K, Cabrera R, Ferrer M, Torres A, Fernandez-Barat L. 2025. Comparative
analysis of illumina and oxford nanopore sequencing platforms for 16S rRNA profiling of
respiratory microbial communities. Sci Rep 15:33688.

19. molzym. Automated Sample Pre-treatment, Bacterial / Fungal DNA Isolation and PCR Analysis.

20. Bouchiat C, Ginevra C, Benito Y, Gaillard T, Salord H, Dauwalder O, Laurent F, Vandenesch F. 2022.
Improving the Diagnosis of Bacterial Infections: Evaluation of 16S rRNA Nanopore Metagenomics
in Culture-Negative Samples. Front Microbiol 13.

21. Gupta A, Cooper VS, Zemke AC. 2025. Evaluation of V3–V4 and FL-16S rRNA amplicon sequencing
approach for microbiota community analysis of tracheostomy aspirates. mSphere 0:e00388-25.

        13/16

22. Winand R, Bogaerts B, Hoffman S, Lefevre L, Delvoye M, Van Braekel J, Fu Q, Roosens NH, De
Keersmaecker SC, Vanneste K. 2020. Targeting the 16S rRNA Gene for Bacterial Identification in
Complex Mixed Samples: Comparative Evaluation of Second (Illumina) and Third (Oxford
Nanopore Technologies) Generation Sequencing Technologies. 1. International Journal of
Molecular Sciences 21:298.

23. Achermann Y, Goldstein EJC, Coenye T, Shirtliff ME. 2014. Propionibacterium acnes: from
Commensal to Opportunistic Biofilm-Associated Implant Pathogen. Clinical Microbiology
Reviews 27:419–440.

24. Han H-S, Ro DH, Chung J, Kim N, Moon J. 2022. Nanopore 16S amplicon sequencing enables rapid
detection of pathogen in knee periprosthetic joint infection. International Journal of Medical
Microbiology 312:151570.

25. Moon J, Kim N, Kim T-J, Jun J-S, Lee HS, Shin H-R, Lee S-T, Jung K-H, Park K-I, Jung K-Y, Kim M, Lee
SK, Chu K. 2019. Rapid diagnosis of bacterial meningitis by nanopore 16S amplicon sequencing:
A pilot study. International Journal of Medical Microbiology 309:151338.

26. Jang Y, Kim S, Kim N, Son H, Ha EJ, Koh EJ, Phi JH, Park C-K, Kim JE, Kim S-K, Lee SK, Cho W-S,
Moon J, Chu K. 2022. Nanopore 16S sequencing enhances the detection of bacterial meningitis
after neurosurgery. Annals of Clinical and Translational Neurology 9:312–325.

27. Wang M, Fu A, Hu B, Shen G, Liu R, Zhao W, Jiang S, Cai X, Li C, Li J, Wu Q, Feng K, Gu J, Chen J,
Shu M, Zhang B, Deng Z, Yu L, Li Y, Liu T. 2020. Same-Day Simultaneous Diagnosis of Bacterial and
Fungal Infections in Clinical Practice by Nanopore Targeted Sequencing. medRxiv
https://doi.org/10.1101/2020.04.08.20057604.

28. Vanhee M, Floré K, Vanthourenhout S, Hellemans J, Muyldermans A, Reynders M. 2024.
Implementation of full-length 16S nanopore sequencing for bacterial identification in a clinical
diagnostic setting. Diagnostic Microbiology and Infectious Disease 108:116156.

29. Baldan R, Cliff PR, Burns S, Medina A, Smith GC, Batra R, Cerda A, Wilson R, Merrill T, Lewis SJ,
Patel A, Jeyaratnam D, Wyncoll DL, Barrett N, Chand MA, Edgeworth JD. 2021. Development and
evaluation of a nanopore 16S rRNA gene sequencing service for same day targeted treatment of
bacterial respiratory infection in the intensive care unit. Journal of Infection 83:167–174.

30. Curry KD, Wang Q, Nute MG, Tyshaieva A, Reeves E, Soriano S, Wu Q, Graeber E, Finzer P,
Mendling W, Savidge T, Villapol S, Dilthey A, Treangen TJ. 2022. Emu: species-level microbial
community profiling of full-length 16S rRNA Oxford Nanopore sequencing data. Nat Methods
19:845–853.

31. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. 2013. The SILVA
ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic
Acids Res 41:D590–D596.

32.   Yilmaz P, Parfrey LW, Yarza P, Gerken J, Pruesse E, Quast C, Schweer T, Peplies J, Ludwig W,
Glöckner FO. 2014. The SILVA and "All-species Living Tree Project (LTP)" taxonomic frameworks.
Nucleic Acids Res 42:D643–D648.

33.   McDonald D, Jiang Y, Balaban M, Cantrell K, Zhu Q, Gonzalez A, Morton JT, Nicolaou G, Parks DH,
Karst SM, Albertsen M, Hugenholtz P, DeSantis T, Song SJ, Bartko A, Havulinna AS, Jousilahti P,
Cheng S, Inouye M, Niiranen T, Jain M, Salomaa V, Lahti L, Mirarab S, Knight R. 2024. Greengenes2
unifies microbial data in a single reference tree. Nat Biotechnol 42:715–718.

6 Figure legends

Figure 1. Overview of the laboratory and bioinformatic workflows. A) Investigated were dilutions series of pure liquid cultures of *E. coli* and *S. aureus*, as well as over 100 clinical samples from routine diagnostics. The DNA was extracted and the 16S rRNA amplified with the Molzym Micro-Dx kit. The resulting amplicons were sequenced with both ONT and Illumina MiSeq. **B**) All raw sequencing data was quality filtered and length filtered. Illumina reads were additionally subsampled to 9,000 reads before further processing. The DADA2 tool was used to generate amplicon sequence variants (ASVs) from the Illumina reads and the LORCAN pipeline was used for the ONT reads. The taxonomy of the consensus sequences was determined using BLAST. For further analysis only species associated with more than 100 reads were kept. The Figure was created with BioRender https://BioRender.com.

Figure 2. Sensitivity and specificity based on dilutions series of pure bacterial liquid cultures. Serial dilutions for *E. coli*, *S. aureus* and a mixture of both were prepared and subjected to our laboratory and bioinformatic workflows (**Fig. 1**). Reads assigned to *Escherichia* sp. and *Shigella* sp. were grouped into *Escherichia* sp. due to their high similarity of the 16S rRNA gene across said species. Similarly, *Corynebacterium* species were grouped together. Species with less than 100 reads in one sample are not displayed. At the bottom of the figure the observed number of CFUs (colony forming units) per ml of the diluted liquid cultures are shown.

Figure 3. Detected bacterial species in routine clinical samples. A) Venn-diagram of the number of species shared between sequencing methods in clinical samples (n=101). In parentheses the percentages of all the species across samples are given for each case. The total number of detected species is 167. **B)** Species prevalence (i.e. percent of samples in which a species is present) across sequencing technologies. The average relative abundance across the samples in which a species was found present is indicated by a color range (red = 100%, blue = 0%). Only species that are present in at least 3 samples in at least one method are depicted. **C)** Barplots of the summed relative abundances of detected species across all samples for each of the sequencing methods. Shown are the 12 most abundant species, the remaining are grouped into the category "Other". **D)** Boxplot of the number of species identified by sequencing method, grouped by antibiotic pre-treatment of the samples and by the results of the clinical assessment. Each dot represents an individual sample, with the shape denoting the availability of culture-based identification results. No significant difference between antibiotic treatments in either of the methods could be detected. The number of species was significantly higher in samples where a likely contamination was detected, in contrast to a reasonable pathogen for both Illumina (p=0.02) and ONT (p=0.03).

16/16

Figure 1

A) Laboratory Methods

Liquid culture → Dilutions (10⁻⁵, 10⁻⁶, 10⁻⁷) → Aliquoted into Triplicates

Clinical Sample

DNA extraction → 16S PCR amplification

ONT Sequencing

Illumina MiSeq Sequencing

B) Bioinformatic Methods

Illumina MiSeq reads

Trim, quality filter and min length filter

Subsample to 9'000 reads

Denoise and merge (F&R) with DADA2 to find Amplicon sequence variants (ASVs)

Min length filter

BLAST to determine taxonomy

Filter out species with < 100 reads

ONT reads

LORCAN

Quality & length filter

Subsample to 9'000 reads

Group reads into species by mapping to reference sequences

Consensus sequence generation for each group (>100 reads)

BLAST to determine taxonomy

Figure 2

Figure 3